Inflammatory Bowel Disease

Top Story

Skipping biologics just four times per month puts IBD patients at risk for flare

December 13, 2017

Patients with inflammatory bowel disease receiving subcutaneous anti-tumor necrosis factor therapy are at a significantly increased risk for disease flare if they miss their medication just 4 days per month, according to new research published in the American Journal of Gastroenterology.

Notably, investigators found that more than 20% of patients who received these drugs fell below this adherence threshold, highlighting the need for interventions to improve adherence and thus prevent hospitalizations and the need for steroids.

Diet in IBD: An important component to stabilize the microbiome

December 8, 2017
In patients with inflammatory bowel disease, diet significantly impacts the fecal microbiome, which is believed to be involved in triggering and maintaining…
In the Journals

Switching from Remicade to biosimilar Inflectra safe, effective through 1 year in IBD

December 7, 2017
Patients with inflammatory bowel disease who switched from Remicade to Inflectra showed no differences in drug levels or disease activity through 1 year of follow-up…
In the Journals

Remicade, Entyvio ranked best first-line agents for moderate-to-severe UC

December 5, 2017
Based on indirect comparisons, Remicade and Entyvio were the most effective first-line therapies for inducing remission and mucosal healing in moderate-to-severe…
More Headlines »
CME

The JAK-STAT Pathway in Inflammatory Bowel Disease: Expert Insights and Discussion of the Latest Research

This activity is supported by an independent educational grant from Pfizer.

Russell D. Cohen, MD, and Thomas A. Ullman, MD, summarize clinical data on JAK inhibitors in inflammatory bowel disease…
More »
GI Bookshelf

Chapter 31: Rectal Bleeding Following Craniotomy

From Complicated Cases in GI
More »
Resource Centers
Advances in IBD

Advances in IBD

Video
Meeting News

VIDEO: Nutrition therapy for pediatric IBD continues to advance

November 17, 2017
More »
Advertisement
Advertisement